Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Sirona Biochem Appoints David Moore to Board of Directors
Jan 23, 2014 15:20:00 (ET)
Sirona Biochem Appoints David Moore to Board of Directors
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jan 23, 2014) - Sirona Biochem Corp. (TSX VENTURE:SBM)(OTCQX:SRBCF) announced today the appointment of David Moore to its Board of Directors.
"We are very fortunate to have David Moore join us," said Neil Belenkie, Chief Executive Officer of Sirona Biochem. "David's previous experience and success in the USA leading many of the tasks that we are about to undertake, are unique and invaluable resources to Sirona's leadership team. With David on board, we gain another level of confidence in our ability to execute our strategy."
About David Moore
David joins the board of directors with significant biotech and big pharma experience. David is currently Chief Commercial Officer of Cempra, a clinical-stage pharmaceutical company focused on developing antibacterials to meet critical medical needs. Prior to joining Cempra, David was Chief Business Officer of Ocera Therapeutics, a publicly traded clinical stage biotech focused in advanced liver disease. Prior to Ocera, he was Chief Business Officer of Tranzyme Pharma, a publicly traded clinical stage biotech and macrocyclic discovery chemistry company which David and the management team successfully merged with Ocera Therapeutics in July 2013. David has participated in several rounds of corporate financing, successfully negotiated multiple license deals for both clinical stage products and pre-clinical compounds in addition to the recent strategic merger process. David has an extensive commercial background having spent over 15 years developing and managing pharmaceutical commercial programs with the majority of that time spent with Ortho-McNeil and Janssen divisions of Johnson & Johnson. David received his B.Sc. in Biology from Towson University and an M.B.A. from Lehigh University, and a second graduate degree in Health Policy Excellence from Thomas Jefferson University.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements.
Sirona Biochem Corp.
Christopher Hopton
CFO
1.604.282.6064
chopton@sironabiochem.com
www.sironabiochem.com
(MORE TO FOLLOW) Dow Jones Newswires
January 23, 2014 15:20 ET (20:20 GMT)
Sirona shareholder update webinar.
http://www.sironabiochem.com/sirona-shareholder-update-webinar/
So when the private placement closes we should be around 141mil shares outstanding?
Sirona enters environmental collaboration to develop anti-aging compounds for the future
By Andrew McDougall+, 16-Jan-2014
On the back of its work on anti-aging glycoproteins from Antarctic fish which attracted attention from L’Oréal, Sirona Biochem has now teamed up with Explore Green and environmentalists Jean-Michel and Fabien Cousteau to advance its work.
http://www.cosmeticsdesign.com/Business-Financial/Sirona-enters-environmental-collaboration-to-develop-anti-aging-compounds-for-the-future
"Our shared goal is to create an anti-aging skin treatment that presents unparalleled efficacy and commercial opportunity for the predicted $300 billion dollar anti-aging global market."
Sirona Biochem Announces License Agreement with Cincinnati Children's Hospital Medical Center
Jan 15, 2014 07:45:00 (ET)
Sirona Biochem Announces License Agreement with Cincinnati Children's Hospital Medical Center
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jan 15, 2014) - Sirona Biochem Corp. (TSX VENTURE:SBM)(OTCQX:SRBCF) and Cincinnati Children's Hospital Medical Center announce the formalization of a license agreement of Cincinnati Children's patented synthetic vernix technology.
Sirona Biochem plans to create an anti-aging skin care treatment that combines their patented cell preservation glycoprotein with Cincinnati Children's technology.
Sirona will lead the development, with support from Cincinnati Children's, of the anti-aging cream incorporating the proprietary technologies of each organization. The resulting new anti-aging product will be patented with the goal of licensing the new technology to a global leader in the cosmetic and consumer packaged good marketplaces.
It is expected by both Sirona and Cincinnati Children's that new patents and applications (cosmetic and therapeutic) for this combined technology may be discovered and the collaboration is structured to support the goal of future commercial revenue from multiple sources.
"We are proud to be working in partnership with Cincinnati Children's Hospital Medical Center, a world leader in patient care and breakthrough research," said Neil Belenkie, CEO of Sirona Biochem. "Our shared goal is to create an anti-aging skin treatment that presents unparalleled efficacy and commercial opportunity for the predicted $300 billion dollar anti-aging global market."
"We are excited to formalize this agreement with Sirona Biochem and look forward to continuing to work together," said Niki Robinson, PhD, assistant vice president of Cincinnati Children's Center for Technology Commercialization.
About Sirona Biochem
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France. The company specializes in the stabilization of carbohydrate molecules, with the goal of improving compounds' efficacy and safety. Sirona Biochem's compounds are patented as new chemical entities for maximum commercial protection and revenue potential. Newly developed compounds are licensed to leading companies around the world in return for licensing and milestone fees and ongoing royalty payments. TFChem, Sirona Biochem's wholly-owned French laboratory is a recipient of multiple French national scientific awards and a European Union and French government grant. For more information visit www.sironabiochem.com.
About Cincinnati Children's Hospital Medical Center
Cincinnati Children's Hospital Medical Center ranks third in the nation among all Honor Roll hospitals in U.S. News and World Report's 2013 Best Children's Hospitals ranking. It is ranked #1 for cancer and in the top 10 for nine of 10 pediatric specialties. Cincinnati Children's, a non-profit organization, is one of the top three recipients of pediatric research grants from the National Institutes of Health, and a research and teaching affiliate of the University of Cincinnati College of Medicine. The medical center is internationally recognized for improving child health and transforming delivery of care through fully integrated, globally recognized research, education and innovation. Additional information can be found at www.cincinnatichildrens.org. Connect on the Cincinnati Children's blog, via Facebook and on Twitter.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
Sirona Biochem Corp.
Christopher Hopton
CFO
1.604.282.6064
chopton@sironabiochem.com
www.sironabiochem.com
(MORE TO FOLLOW) Dow Jones Newswires
January 15, 2014 07:45 ET (12:45 GMT)
Sirona Biochem Announces Collaboration with Jean-Michel Cousteau, Fabien Cousteau, and Explore Green
Jan 13, 2014 07:45:00 (ET)
Sirona Biochem Announces Collaboration with Jean-Michel Cousteau, Fabien Cousteau, and Explore Green
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jan 13, 2014) - Sirona Biochem Corp. (TSX VENTURE:SBM)(OTCQX:SRBCF) announces a collaboration with Jean-Michel Cousteau, Fabien Cousteau, (respective son and grandson of Jacques Cousteau) and Explore Green LLC.
Jean-Michel Cousteau and Fabien Cousteau will become Brand Ambassadors for Sirona Biochem and Explore Green will leverage its media, scientific and commercial contacts to broadcast our partnership's alliance and goals. Sirona Biochem will contribute its cosmetic, pharmaceutical and scientific expertise and Sirona will become a primary scientific resource for the potential commercialization of new technologies discovered by the Cousteaus, Explore Green and their network.
"Our oceans cover more than 70% of the surface of Earth, yet we have explored less than 5% of it," said Jean-Michel Cousteau. "The future solutions to human health and our quality of life still remain to be discovered. Sirona Biochem is working to investigate the great resources of our ocean for all mankind. I applaud their effort to learn from the ocean without taking from the ocean."
Interest in Sirona by the Cousteaus began with a glycoprotein isolated from Antarctic fish that acts as a natural "anti-freeze". This compound, successfully synthesized by Sirona, has widespread potential use in cosmeceuticals and perhaps pharmaceuticals. In laboratory development, the compound does not require harvesting any fish-a critical distinction due to rapid fish species depletion due to over-fishing and other human induced problems.
Goals of the collaboration also include establishing the criteria for an environmentally-friendly product accreditation by Jean-Michel and Fabien Cousteau. Sirona Biochem's anti-aging glycoprotein will be the first compound assessed using the newly developed criteria in the hopes that it will become the first Cousteau accredited-cosmetic compound in the world.
Another goal is to educate multi-national corporations, global consumers and academia that sensitive environments such as oceans and rainforests may be the greatest source of healthcare and therapeutic solutions available to the world; but the challenge is to learn from these sensitive environments without depleting their natural resources. Sirona represents a research and development leader who has accomplished this goal already.
About Jean Michel Cousteau
Explorer. Environmentalist. Educator. Film Producer. For more than four decades, Jean-Michel Cousteau has dedicated himself and his vast experience to communicate to people of all nations and generations his love and concern for our water planet.
Since first being "thrown overboard" by his father at the age of seven with newly invented SCUBA gear on his back, Jean-Michel has been exploring the ocean realm. The son of ocean explorer Jacques Cousteau, Jean-Michel has investigated the world's oceans aboard Calypso and Alcyone for much of his life. Honoring his heritage, Jean-Michel founded Ocean Futures Society in 1999 to carry on this pioneering work.
Ocean Futures Society, a non-profit marine conservation and education organization, serves as a "Voice for the Ocean" by communicating in all media the critical bond between people and the sea and the importance of wise environmental policy. As Ocean Future's spokesman, Jean-Michel serves as an impassioned diplomat for the environment, reaching out to the public through a variety of media. For more on Ocean Futures Society, go to: www.oceanfutures.org.
About Fabien Cousteau
Growing up on the decks of his famous Grandfather's ships, Calypso and Alcyone, Fabien Cousteau was destined to work at protecting our planet's immense and endangered marine habitats. Fabien champions the family legacy as third generation ocean explorer and filmmaker. He is the founder of Plant A Fish, a non-profit whose initiatives empower and educate local communities around the world to "re-plant" aquatic species of plants and animals in environmentally stressed areas to make a positive impact. For more information about Plant A Fish go to: www.plantafish.org.
About Explore Green
Explore Green(TM) is a worldwide resource of the leading names and creativity about the environment and exploration. We represent scientists, adventurers, eco-celebrities, climatologists and some of the top thinkers on the planet... about the planet. With the increasing fusion of entertainment, politics and the environment, Explore Green(TM) gives businesses, associations and groups of all kinds access to those innovators and visionaries on topics from climate change and depletion of species to meeting global resource demands and going to new heights in space and the depths of the ocean. For more information about Explore Green, go to: www.exploregreen.com.
About Sirona Biochem
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France. The company specializes in the stabilization of carbohydrate molecules, with the goal of improving compounds' efficacy and safety. Sirona Biochem's compounds are patented as new chemical entities for maximum commercial protection and revenue potential. Newly developed compounds are licensed to leading companies around the world in return for licensing and milestone fees and ongoing royalty payments. TFChem, Sirona Biochem's wholly-owned French laboratory is a recipient of multiple French national scientific awards and a European Union and French government grant. For more information visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
Sirona Biochem Corp.
Christopher Hopton
CFO
1.604.282.6064
chopton@sironabiochem.com
www.sironabiochem.com
(MORE TO FOLLOW) Dow Jones Newswires
January 13, 2014 07:45 ET (12:45 GMT)
cool! just got back in,good volume
!!!VOLUME!!! 88,000% MORE VOLUME THAN USUAL TO BE EXACT LOL
Sirona Biochem Announces CAD$5.3 Million Private Placement
Jan 08, 2014 17:32:00 (ET)
Sirona Biochem Announces CAD$5.3 Million Private Placement
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jan 8, 2014) - Sirona Biochem Corp. (TSX VENTURE:SBM)(OTCQX:SRBCF)(FRANKFURT:ZSB), (the "Company") announced today a non-brokered private placement of up to 33,400,000 units of the Company at a price of $0.16 CAD each (a "Unit") for gross proceeds of up to CAD$5,344,000 (the "Private Placement").
Each Unit will consist of one common share of the Company (a "Share") and one-half of one transferable share purchase warrant (a complete warrant shall be referred to as a "Warrant"). Each Warrant will entitle the holder to purchase one additional Share of the Company at any time for three years from the closing date of the Private Placement at a price of CAD$0.27 per Share.
The Company is proposing to pay a finder's fee to an agent or agents that assist in procuring the proceeds of the offering. Such Fee shall consist of a cash fee equal to no more than 8% of the total proceeds of the Private Placement placed by such finder and warrants up to 8% of the number of Units the finder sells in the Private Placement (the "Finder's Warrants"). The Finder's Warrants will be exercisable into one-half of one additional Share of the Company at a price of CAD$0.27 per Share for a period of 3 years from the closing date of the Private Placement.
The Company intends to use the proceeds from the Private Placement to support business growth through expansion of TFChem, the wholly owned subsidiary in France. Proceeds will also support phased hiring of 28 new employees in TFChem and secure operating costs of Sirona and TFChem for 2 years.
All securities to be issued under the Private Placement will be subject to a hold period in accordance with the Toronto Stock Exchange Venture ("TSXV") and/or other regulatory requirement. Closing of the Private Placement is subject to customary conditions, including TSXV acceptance.
This news release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the Shares in any jurisdiction in which such offer, solicitation or sale would be unlawful. The Shares have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws and may not be offered or sold within the United States or to, or for the benefit of, U.S. persons (as defined in Regulation S under the U.S. Securities Act) unless registered under the U.S. Securities Act and applicable state securities laws or pursuant to an exemption from such registration requirements.
About Sirona Biochem
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France. The company specializes in the stabilization of carbohydrate molecules, with the goal of improving compounds' efficacy and safety. Sirona Biochem's compounds are patented as new chemical entities for maximum commercial protection and revenue potential. Newly developed compounds are licensed to leading companies around the world in return for licensing and milestone fees and ongoing royalty payments. TFChem, Sirona Biochem's wholly-owned French laboratory is a recipient of multiple French national scientific awards and a European Union and French government grant. For more information visit www.sironabiochem.com.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
Sirona Biochem Corp.
Christopher Hopton
CFO
604.282.6064
chopton@sironabiochem.com
www.sironabiochem.com
(MORE TO FOLLOW) Dow Jones Newswires
January 08, 2014 17:32 ET (22:32 GMT)
The Company intends to use the proceeds from the Private Placement to support business growth through expansion of TFChem, the wholly owned subsidiary in France. Proceeds will also support phased hiring of 28 new employees in TFChem and secure operating costs of Sirona and TFChem for 2 years.
cant wait for them to start making$$ when those l.o.i. sbegin to make $$$$ id love to see a dollar down the road
Buc, Things are starting to look brighter for Sirona
they turn from research/development to $$ producing,would love to see a dollar here before years end
I believe this is the year for Sirona. Hopefully we see some more positive developments soon.
come on 2014...will be $$ producing and not r&d
what timeframe are we working with? or the company working with?
ive a buy order in,my other didn't get filled as it gapped up
Sirona Biochem Announces Signing of Deal for Collaboration with Bloom Burton & Co.
VANCOUVER, BRITISH COLUMBIA, Dec 04, 2013 (Marketwired via COMTEX) -- Sirona Biochem Corp. CA:SBM -3.33% (otcqx:SRBCF) and Bloom Burton & Co. ("Bloom Burton") announce the signing of a joint venture to conduct collaborative research to develop and commercialize new therapeutics in the areas of inflammation and infectious disease.
Sirona and Bloom Burton will identify and design numerous different anti-inflammatory and anti-infective compounds. Sirona will be responsible for the chemistry, using its proprietary expertise in fluorination technology. Bloom Burton will be responsible for financing, clinical validation and commercialization of the compounds. At present, there are unmet market needs in the areas of rare or neglected inflammatory diseases and bacterial resistance. With the former, often overlooked and the latter, an emerging threat, the collaboration between Sirona and Bloom Burton will endeavor to help minimize the medical gap by maximizing on each of the companies' core competencies.
"We are extremely excited to be working alongside Bloom Burton, a national leader in healthcare-specialized investment banking" said Neil Belenkie, CEO of Sirona Biochem. "This joint venture will combine the best of our expertise to develop the compounds, expanding our product portfolio and delivering innovative solutions in therapeutic areas with unmet needs."
"We have always appreciated the strength of Sirona's chemistry platform and we are excited to explore opportunities in two important and unmet therapeutic indications," said Brian Bloom, President of Bloom Burton & Co. "In addition to capital raising, advisory, equity research and direct investments, Bloom Burton is excited to expand its activities to include company creation and incubation, which should create value for Sirona shareholders and our firm."
About Bloom Burton & Co.
Bloom Burton & Co. exists to accelerate monetization in healthcare. Bloom Burton has an experienced team of medical, scientific, pharmaceutical, legal and capital markets professionals who perform a deeper level of diligence, which combined with a creative and entrepreneurial culture, leads to the right monetizing events for companies and investors. Bloom Burton's many services include capital raising, mergers and acquisitions advisory, equity research, scientific and medical consulting, direct investing, company creation and incubation. For more information, please visit www.bloomburton.com.
About Sirona Biochem
Sirona Biochem is not a traditional biotech company. Sirona is a product-pipeline company with a proprietary technology platform developed at its laboratory facility in France. The company specializes in the stabilization of carbohydrate molecules, with the goal of improving compounds' efficacy and safety. Sirona Biochem's compounds are being developed for both pharmaceutical and cosmetic marketplaces and are patented as new chemical entities for maximum commercial protection and revenue potential. Newly developed compounds are licensed to leading companies around the world in return for licensing and milestone fees and ongoing royalty payments. TFChem, Sirona Biochem's wholly-owned French laboratory is a recipient of multiple French national scientific awards and a European Union and French government grant. For more information visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
Contacts:
Antonia Issa
Communications Manager
Sirona Biochem Corp.
1.604.282.6065
aissa@sironabiochem.com
SOURCE: Sirona Biochem Corp.
(C) 2013 Marketwire L.P. All rights reserved.
Sirona Biochem Appoints Nigel Terrett to Board of Directors
VANCOUVER, BRITISH COLUMBIA, Nov 28, 2013 (Marketwired via COMTEX) -- November 28, 2013 - Sirona Biochem Corp. CA:SBM -6.25% (otcqx:SRBCF) announced today the appointment of Nigel Terrett to its Board of Directors.
"We are thrilled that Nigel Terrett has agreed to join the team," said Neil Belenkie, Chief Executive Officer of Sirona Biochem. "Nigel's background in implementing successful strategic plans in life sciences, and his existing in-depth knowledge of Sirona through his work as our Strategic Advisor, will be an asset to us as we move forward in the growth and expansion of our business."
Sirona Biochem also announces that Chris Verrico will be stepping down from the company's Board of Directors. The company would like to extend its thanks and gratitude for his contribution.
About Nigel Terrett
Nigel Terrett has held many leadership roles in the life sciences sector some of which include his role of Chief Strategic Officer of LifeLabs Inc., Chairman of the Board at Excelleris Technologies, Senior Vice President of MDS Diagnostics Inc., and CIO within MDS Health Group. More recently, Nigel has provided strategic advisory services to the Biotech industry.
Contacts:
Antonia Issa
Communications Manager
Sirona Biochem Corp.
Phone: 1.604.282.6065
Email: aissa@sironabiochem.com
SOURCE: Sirona Biochem Corp.
(C) 2013 Marketwire L.P. All rights reserved.
Sirona Biochem Corp. : Sirona Grants Stock Options
Vancouver, British Columbia - November 22, 2013 - Sirona Biochem Corp. (TSX-V: SBM, OTCQX: SRBCF, Frankfurt: ZSB), (the "Company") announces that is has granted, under its stock option plan, incentive stock options to directors, officers and consultants for the purchase of up to 2,150,000 common shares of the Company at a price of $0.15 per share for a period of five years.
About Sirona Biochem Corp.
Sirona Biochem is not a traditional biotech company. Sirona is a product-pipeline company with a proprietary technology platform developed at its laboratory facility in France. The company specializes in the stabilization of carbohydrate molecules, with the goal of improving compounds' efficacy and safety. Sirona Biochem's compounds are being developed for both pharmaceutical and cosmetic marketplaces and are patented as new chemical entities for maximum commercial protection and revenue potential. Newly developed compounds are licensed to leading companies around the world in return for licensing and milestone fees and ongoing royalty payments. TFChem, Sirona Biochem's wholly-owned French laboratory is a recipient of multiple French national scientific awards and a European Union and French government grant. For more information visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information regarding this press release, contact:
Antonia Issa
Communications Manager
Sirona Biochem Corp.
Phone: 1.604.282.6065
Email: aissa@sironabiochem.com
---------------
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
PRESS RELEASE
Oct. 15, 2013, 7:46 a.m. EDT
Sirona Biochem Corporation-CEO's Report on Progress
VANCOUVER, BRITISH COLUMBIA, Oct 15, 2013 (Marketwired via COMTEX) -- Sirona Biochem Corp. CA:SBM 0.00% (otcqx:SRBCF)(frankfurt:ZSB) today provided a business update.
I'd like to take this opportunity to summarize Sirona Biochem's business and strategic growth over the past 12 months.
Financial
In October 2012, Sirona Biochem's share price hit a low of 4 cents and our market cap was $3 million CDN. We made the decision to raise money using a debt instrument to avoid a punitive equity financing. We raised $600,000 in debt which gave us the financial runway to grow the value of the company to a high of 14 cents per share and a market cap of more than $11 million on January 18th 2013.
February 22, 2013 we announced an equity financing target of $2.7 million and we closed the second tranche of this financing on April 30, 2013 having raised $1.8 million in equity.
September 11, 2013 we announced an equity financing target of $1 million and we oversubscribed the private placement, closing on September 19th having raised $1.17 million.
On October 11, 2013, Sirona's share price was 16.5 cents and our market cap was $17.83 million CDN, representing an increase in market capitalization of $14,644,394.00 CDN and a market capitalization increase of 560%.
As of October 11, 2013, Sirona Biochem's running 3 month average trading volume was in excess of 500,000 shares per day.
Strategy
The decision was made in November 2012 that we would de-risk our business model and simplify our operations.
Sirona' Biochem's business model:
Sirona Biochem's expertise is in creating new chemical compounds (pharmaceutical and cosmetic) that have distinct advantages over existing technologies. Each compound that we create will be licensed to an industry-leading company who will be responsible for developing, manufacturing and selling the compound. In return for the licenses, Sirona will receive licensing fees, milestone payments and ongoing royalty payments. The more compounds Sirona Biochem creates, the more revenue streams Sirona Biochem receives.
With this level of strategic focus, we diversify our risk across multiple projects, increase our portfolio size more quickly and continue to build our credibility and reputation as experts in the discovery of innovative therapeutics.
Operations
In November 2012 we restructured the company and downsized our corporate head office by one position. In our laboratory in France we assessed every project in development and made the decision to focus our resources on two projects (SGLT2 inhibitor and skin lightening) to ensure each would be completed and available for transaction within 6 months. All other projects were assigned a timeline for re-insertion into the development pipeline contingent upon the successful completion of our two prioritized projects.
Business Development
In the last 12 months we have attended / presented at the following meetings, conferences and events:
-- In Cosmetics Asia (Thailand)
-- In Cosmetics Europe (France)
-- Bio Partnering North America (Vancouver)
-- BioPharm America (Boston)
-- BIO International Convention (Chicago)
-- BIOTECanada CEO Summit (Chicago)
-- BioInvestor Forum (San Francisco)
-- Beijing, Tianjin, Guangzhou, Shanghai, China (2 trips - business
development and investor relations)
-- Paris, Rouen, France (5 trips - business development and management of
TFChem)
-- New York, USA (4 trips - investor relations and setting up strategic
relationships)
-- Tokyo, Yokohama, Japan (business development)
-- California, USA (3 trips - business development and investor relations)
-- Toronto, Canada (business development and investor relations)
-- London, UK (Cosmetic Business Innovation Awards - Sirona Biochem's skin
lightening compound was a finalist in the Innovation in Ingredients
category, competing against Dow Chemical, Dove Spa, Mibelle Biochemistry
and Seppic)
Our process for maximizing the potential value of our compounds is as follows: we connect with as many pharmaceutical, biotech, cosmetic and consumer health companies as possible that may have interest in our technology. Starting all of these discussions in parallel enables us to move the conversations forward within a predictable window of opportunity. These concurrent conversations create a competitive environment for our technology, maximizing its value within the marketplace.
Summary:
As a result of our international team's efforts, in the last 7 months Sirona Biochem has announced the following:
-- Material Transfer Agreement with VitamFero, a member of Genopole, for
testing of our biological preservation technology in combination with
their live attenuated animal vaccines.
-- Letter of Intent (LOI) with Biogalenys to develop preclinical data
supporting multiple applications of Sirona Biochem's glycoprotein (cell
preservation technology).
-- Letter of Intent (LOI) with Cincinnati Children's Hospital Medical
Center, the #3 ranked hospital among all honor roll hospitals in the
USA. The goal of our collaboration is to combine our proprietary
technologies to create a novel skin care technology which will be
commercialized by a global leader in cosmetic or consumer packaged goods
sales.
-- Letter of Intent (LOI) with Wanbang Pharma, China's number one ranked
anti-diabetic company. Wanbang Pharma will receive an exclusive license
for sales of Sirona Biochem's SGLT2 Inhibitor in the People's Republic
of China in return for licensing and clinical milestone fees and ongoing
royalty payments. Wanbang Pharma will be responsible for funding all
clinical studies and development of the SGLT2 Inhibitor and Sirona
Biochem will receive all of the data generated by Wanbang Pharma with
the goal of exponentially raising the value of Sirona Biochem's SGLT2
Inhibitor for licensing agreements throughout the rest of the world.
-- Letter of Intent (LOI) with Obagi Medical Products for a global
exclusive license of Sirona Biochem's skin lightening compound TFC-849.
Obagi Medical Products will be responsible for all development,
manufacturing and sales of the compound and in return Sirona Biochem
will receive licensing and milestone fees and ongoing royalty payments.
-- Letter of Intent (LOI) to create a joint venture with Bloom Burton and
Co., Canada's largest and most active healthcare-specialized investment
banking group. The goal of this joint venture is to conduct
collaborative research to develop and commercialize new therapeutics in
the areas of inflammation and infectious disease.
Moving forward we are strategically and operationally optimized to transition Sirona Biochem to its next phase of growth. Our short term focus is to formalize each of the LOIs that we have signed, confirming Sirona Biochem's first commercial transactions and predictable revenue streams. These formal agreements will mark the final transition from our being a research and development operation to a revenue generating business with globally recognized and respected brands as our partners.
Our near term goals include setting up future pipeline projects and growing our R&D infrastructure. In the next 30 months we plan to add 28 new employees and almost triple the size of TFChem, our laboratory in France. We are working now to fill our development pipeline with projects for our new chemistry teams. This growth plan is tied directly to our goal of significantly increasing the number of projects we are able to undertake concurrently. The greater the number of compounds we create, the greater the number of transactions and revenue generating partnerships that will drive our business growth and shareholder value.
Our overarching goal is for Sirona Biochem to become recognized as a global leader in the discovery of new products for leading cosmetic and pharmaceutical brands. Continued success creating commercially innovative and lucrative products for global brands will make Sirona Biochem a prized resource for the world's largest companies.
Best Regards,
Neil Belenkie, CEO
Sirona Biochem
About Sirona Biochem Corp.
Sirona Biochem is not a traditional biotech company. Sirona is a product-pipeline company with a proprietary technology platform developed at its laboratory facility in France. The company specializes in the stabilization of carbohydrate molecules, with the goal of improving compounds' efficacy and safety. Sirona Biochem's compounds are being developed for both pharmaceutical and cosmetic marketplaces and are patented as new chemical entities for maximum commercial protection and revenue potential. Newly developed compounds are licensed to leading companies around the world in return for licensing and milestone fees and ongoing royalty payments. TFChem, Sirona Biochem's wholly-owned French laboratory is a recipient of multiple French national scientific awards and a European Union and French government grant. For more information visit www.sironabiochem.com.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
Contacts:
Antonia Issa
Communications Manager
Sirona Biochem Corp.
1.604.282.6065
aissa@sironabiochem.com
SOURCE: Sirona Biochem Corp.
(C) 2013 Marketwire L.P. All rights reserved.
LOI WITH BLOOM BURTON
Sirona Biochem Announces LOI for Collaboration With Bloom Burton & Co.
1 hour ago - ACQUIREMEDIA
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Oct. 8, 2013) - Sirona Biochem Corp. (TSX VENTURE:SBM) (OTCQX:SRBCF) (FRANKFURT:ZSB) and Bloom Burton & Co. ("Bloom Burton") announce the signing of a Letter of Intent to conduct collaborative research to develop and commercialize new therapeutics in the areas of inflammation and infectious disease.
Leveraging Sirona's proprietary fluorination technology platform, Sirona and Bloom Burton will identify and design promising assets, undertake chemical synthesis and scale up, and conduct preclinical proof of concept studies necessary to support further development activities. The collaboration hopes to address rare or neglected inflammatory diseases and the threat of emerging bacterial resistance, both of which are markets with enormous medical need. Sirona and Bloom Burton will share in the future proceeds arising from the commercialization activities.
"Bloom Burton is Canada's leading healthcare-specialized investment banking group," said Neil Belenkie, CEO of Sirona Biochem. "We are proud to be developing a collaborative partnership, where our joint expertise will be combined to develop and transact cutting-edge industry solutions in areas with unmet needs."
"One of Bloom Burton's many advantages is that we see the widest range of opportunities spanning early to late stage assets, at private and public companies across all areas of healthcare," said Bloom Burton President, Brian Bloom. "Through this experience, we understand where needs exist in the marketplace and what investors are seeking. We believe Sirona has an excess of therapeutic opportunities than can be exploited by Sirona alone. We are excited to develop these assets in partnership with Sirona and monetize them at the appropriate time."
About Bloom Burton & Co.
Bloom Burton & Co. exists to accelerate monetization in healthcare. Bloom Burton has an experienced team of medical, scientific, pharmaceutical, legal and capital markets professionals who perform a deeper level of diligence, which combined with a creative and entrepreneurial culture, leads to the right monetizing events for companies and investors. Bloom Burton's many services include capital raising, mergers and acquisitions advisory, equity research, scientific and medical consulting, direct investing, company creation and incubation. For more information, please visit www.bloomburton.com.
About Sirona Biochem
Sirona Biochem is not a traditional biotech company. Sirona is a product-pipeline company with a proprietary technology platform developed at its laboratory facility in France. The company specializes in the stabilization of carbohydrate molecules, with the goal of improving compounds' efficacy and safety. Sirona Biochem's compounds are being developed for both pharmaceutical and cosmetic marketplaces and are patented as new chemical entities for maximum commercial protection and revenue potential. Newly developed compounds are licensed to leading companies around the world in return for licensing and milestone fees and ongoing royalty payments. TFChem, Sirona Biochem's wholly-owned French laboratory is a recipient of multiple French national scientific awards and a European Union and French government grant. For more information visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
Major gapper is coming!
BREAKING NEWS - Sirona Biochem_(SBM.V-SRBCF.OTC)_Signs_LOI_with Obagi Medical Products?
Sirona Biochem Signs Letter of Intent with Obagi Medical Products
Sirona Biochem Corp. announced today the signing of a Letter of Intent whereby Sirona Biochem will provide a global exclusive license to Obagi Medical Products to commercialize the skin lightening compound TFC-849. In exchange for this license, Sirona Biochem will receive upfront and milestone payments as well as ongoing royalty payments for global product sales.
“We are thrilled to be partnering with Obagi Medical Products to commercialize our skin lightening technology into a global market projected to reach $19.8 billion by 2018”, said Neil Belenkie, Chief Executive Officer of Sirona Biochem. “Our goal is to grow this relationship, developing a pipeline of leading compounds for Obagi Medical Products for sale around the world”.
About the Betaclear (Skin Lightening) Project
Sirona Biochem's French subsidiary TFChem received a $1.9 million grant in November 2011. This project is co-financed by the European Union and Europe Witnesses in Haute-Normandie with the support of the European Regional Development Fund (E.R.D.F.). A consortium of partners, including the University of Rouen (LMSM EA4312), contract research organization Biogalenys, and TFChem has been assembled to advance this project. The French government and European Union are looking to promote and initiate collaborative projects that are focused on the development of new products and services containing a high level of innovation.
About Sirona Biochem
Sirona Biochem is not a traditional biotech company. Sirona is a product-pipeline company with a proprietary technology platform developed at its laboratory facility in France. The company specializes in the stabilization of carbohydrate molecules, with the goal of improving compounds’ efficacy and safety. Sirona Biochem’s compounds are being developed for both pharmaceutical and cosmetic marketplaces and are patented as new chemical entities for maximum commercial protection and revenue potential. TFChem, Sirona Biochem’s wholly-owned French laboratory is a recipient of multiple French national scientific awards and a European Union and French government grant. For more information visit www.sironabiochem.com.
@0.175 !!!!!!!!!!!!!!!!!!!!!!!!!!!
$SRBCF- Sirona Announces Private Placement
Sep 11, 2013 20:01:16 (ET)
VANCOUVER, BRITISH COLUMBIA, Sep 11, 2013 (Marketwired via COMTEX) -- Sirona Biochem Corp. (otcqx:SRBCF)(frankfurt:ZSB) (the "Company") is pleased to announce that it has arranged, subject to TSX Venture Exchange acceptance, a private placement of up to 8,333,334 units at $0.12 per unit for total gross proceeds of up to $1,000,000. Each unit will consist of one common share of the Company and one transferable share purchase warrant, each warrant is exercisable into one additional common share of the Company for a period of two years from the date of issue at a price of $0.16 per share.
Finders' fees may be payable in whole or in part on the placement pursuant to the policies of the TSX Venture Exchange.
Proceeds of the placement will be used for general working capital.
About Sirona Biochem
Sirona Biochem is not a traditional biotech company. Sirona is a product-pipeline company with a proprietary technology platform developed at its laboratory facility in France. The company specializes in the stabilization of carbohydrate molecules, with the goal of improving compounds' efficacy and safety. Sirona Biochem's compounds are being developed for both pharmaceutical and cosmetic marketplaces and are patented as new chemical entities for maximum commercial protection and revenue potential. TFChem, Sirona Biochem's wholly-owned French laboratory is a recipient of multiple French national scientific awards and a European Union and French government grant. For more information visit www.sironabiochem.com .
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
Contacts:
Sirona Bicohem Corp.
Antonia Issa
Communications Manager
1.604.282.6065
aissa@sironabiochem.com
SOURCE: Sirona Biochem Corp.
Not at all...it's all good
Ive always had urges to play the OTC side ofthis stock. Just never understood if both should be the saem SP, you know what I mean? Now that Sbm.V is at 14.5 again is it jsut a matter of time until SRCBF is as well? U'd think so...
As youve prob guessed Im playing the venture side of this but I hope you dont mind the conversation either way...
My bid is in at .096...we'll see
I thought the saem until thursday and friday. I think some more news is coming...I dont think it would of rebounded the way it has if something isnt up. In fact, I bought more at 14.5 on Friday (on the venture). Rumour has it Neil is quite chapped at the fact that Johnson sold those 2m shares @ 15c saying that they'll regret their decision.
After this little pop we had I hope you took some profits because IMO they'll walk it down for prime pickings time for some cheapies
no...this side SRBCF
Sirona Biochem Signs LOI with China’s #1 Ranked Anti-Diabetic Company, Wanbang Pharma
Vancouver, British Columbia – August 19, 2013 – Sirona Biochem Corp. (TSX-V: SBM, OTCQX: SRBCF) announced today the signing of a Letter of Intent whereby Sirona Biochem will provide an exclusive license to Wanbang Pharma to develop and commercialize Sirona’s SGLT2 Inhibitor in the People’s Republic of China (PRC). In exchange for this license, Sirona Biochem will receive upfront and milestone payments of up to US$9.5M upon successful achievement of development and regulatory milestones and then royalty payments for product sales in the PRC.
Under the terms of the LOI, Wanbang Pharma will assume responsibility for funding and leading all clinical studies required for Chinese Food and Drug Administration approval. Sirona Biochem will be provided all clinical study results to support new regulatory applications outside of PRC.
“We are excited by the opportunity to work with Wanbang Pharma, the leading anti-diabetic company supplying the largest diabetic population in the world,” said Neil Belenkie, Chief Executive Officer of Sirona Biochem. “With more than 90 million people suffering from diabetes in China and the market growing more than 20% per year, we believe that Wanbang Pharma is uniquely positioned to provide maximum potential to commercialize our SGLT2 Inhibitor in the Chinese marketplace”.
About Wanbang Pharma
Wanbang Biopharmaceuticals is a leading pharmaceutical company in China that specializes in research, production and marketing of medicines for diabetes, cardiovascular disease and endocrinology. Among domestic pharmaceutical companies, Wanbang Pharma is the largest manufacturer and marketer of a comprehensive portfolio of drugs for diabetes.
Wanbang Pharma is a subsidiary of Fosun Pharmaceutical Group which is listed on the Shanghai Stock Exchange (SHA:600196). Fosun Pharma, a major shareholder of Sino Pharma (HKG:1099), the largest drug distributor in China, is part of the Fosun Group, the largest non-state owned enterprise group in China which is listed on the Hong Kong stock exchange (HKG:0656).
About Sirona Biochem
Sirona Biochem is a biotechnology company developing diabetes therapeutics, skin depigmenting and anti-aging agents for cosmetic use, biological ingredients and cancer vaccine antigens. The company utilizes a proprietary chemistry technique to improve pharmaceutical properties of carbohydrate-based molecules. Sirona Biochem is the parent company of French-based biotechnology company, TFChem. For more information visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information regarding this press release, contact:
Antonia Issa
Communications Manager
Sirona Biochem Corp.
Phone: 1.604.282.6065
Email: aissa@sironabiochem.com
Good to see at least one person is interested in Sirona...you invested in SRBCF or on the canadian side SBM.V?
Sirona Biochem's Skin Lightening Compounds Proven to be Non-Sensitizers in Safety Assessment
Jul 24, 2013 09:03:30 (ET)
VANCOUVER, BRITISH COLUMBIA, Jul 24, 2013 (Marketwired via COMTEX) -- Sirona Biochem Corp. (otcqx:SRBCF)(frankfurt:ZSB), announced today its skin lightening compounds are non-sensitizers.
Compounds TFC-849 and TFC-723 were tested in a skin sensitization risk assessment, which is an important component of the safety assessment of cosmeceuticals. Sensitization testing measures whether the repeated application of a compound will produce an allergic reaction or immunotoxicity to the skin.
Sirona Biochem conducted its study using a multi-parameter in vitro alternative method developed by the LMSM at the University of Rouen because no in vitro alternative method of testing has been adopted yet by EURL ECVAM (European Union Reference Laboratory for Alternatives to Animal Testing). In the study, the compounds' sensitizer potency was evaluated using a combination of 4 parameters (resorption, haptenation, IL-18 production and cytotoxicity) and a decision table to analyze the compiled results.
Both compounds, TFC-849 and TFC-723, were proven to be non-sensitizers. The study, part of the BetaClear project, funded by a $1.9 million French grant, is led by TFChem, Sirona Biochem's subsidiary, and involves a consortium of partners.
"We are thrilled to be developing a track record of continued positive results in the testing of our compounds, with the newest results showing that our compounds are non-sensitizers," said Neil Belenkie, Chief Executive Officer of Sirona Biochem. "The support of our partners has been essential in the testing of our compounds, and we look forward to the development of a world-class skin lightening product," he added.
According to Global Industry Analysts, the global skin lightening market is estimated to be US$9 billion and is expected to exceed US$19.8 billion by 2018. Fairness products account for over 45 percent of the skincare market and it's estimated that about 15 percent of the global population invests in skin lightening products. Japan has the largest market worldwide for skin lightening, and Asia-Pacific is led by India and China as the fastest growing skin lightening market in the world.
About Sirona Biochem Corp.
Sirona Biochem is a biotechnology company developing diabetes therapeutics, cancer vaccine antigens, skin depigmenting and anti-aging agents for cosmetic use, and biological ingredients. The company utilizes a proprietary chemistry technique to improve pharmaceutical properties of carbohydrate-based molecules. For more information, visit www.sironabiochem.com .
About the Project
Sirona Biochem's French subsidiary TFChem, received a $1.9 million grant in November 2011. This project is co-financed by the European Union and Europe Witnesses in Haute-Normandie with the support of the European Regional Development Fund (E.R.D.F.). A consortium of partners, including the University of Rouen (LMSM EA4312), contract research organization Biogalenys, and TFChem, has been assembled to advance this project. The French government and European Union are looking to promote and initiate collaborative projects that are focused on the development of new products and services containing a high level of innovation.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
Contacts:
Sirona Biochem Corp.
Antonia Issa
Communications Manager
604.282.6065
aissa@sironabiochem.com
www.sironabiochem.com
SOURCE: Sirona Biochem Corp.
mailto:aissa@sironabiochem.com
http://www.sironabiochem.com
Sirona Biochem's Skin Lightening Compounds Demonstrate Significant Antioxidant Properties
Jul 15, 2013 09:03:04 (ET)
VANCOUVER, BRITISH COLUMBIA, Jul 15, 2013 (Marketwired via COMTEX) -- Sirona Biochem Corp. (otcqx:SRBCF)(frankfurt:ZSB), announced today its skin lightening compounds have shown to have significant antioxidant activity. The study was performed by Biogalenys, a France based company ( www.biogalenys.com ). Antioxidant testing measures the ability of a compound to inhibit the oxidation of other molecules. Insufficient levels of antioxidants can cause oxidative stress, which produces free radicals that can be toxic to parts of cells, potentially causing diseases. Antioxidants are being investigated for their abilities to prevent diseases.
In the study, the antioxidant potential of compounds TFC-849 and TFC-723 was evaluated using a standard DPPH assay, and their efficiency factors were determined. The antioxidant activity of the compounds was evaluated by determining resultant levels of IC50, a molar ratio showing the concentration of the antioxidant leading to 50% reduction of the initial DPPH concentration. Both of the company's compounds were proven to have free radical scavenging activity.
While both compounds were qualified as antioxidants, TFC-723 showed to be two times more efficient than both natural alpha and beta arbutin. Moreover, the free radical scavenging activity of TFC-723 was slightly higher than that of Ascorbic Acid Glucoside, commonly used in cosmetic products for this purpose.
"In scientific research, our compounds continue to demonstrate superior efficacy and safety and now show the added benefit of proven antioxidant properties," said Neil Belenkie, Chief Executive Officer of Sirona Biochem. "This is another exciting breakthrough and again raises the bar of quality in a multi-billion dollar industry," he added.
About Sirona Biochem Corp.
Sirona Biochem is a biotechnology company developing diabetes therapeutics, cancer vaccine antigens, skin depigmenting and anti-aging agents for cosmetic use, and biological ingredients. The company utilizes a proprietary chemistry technique to improve pharmaceutical properties of carbohydrate-based molecules. For more information, visit www.sironabiochem.com .
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
Contacts:
Sirona Biochem Corp.
Antonia Issa
Communications Manager
604.282.6065
aissa@sironabiochem.com
www.sironabiochem.com
SOURCE: Sirona Biochem Corp.
mailto:aissa@sironabiochem.com
http://www.sironabiochem.com
$SRBCF - Acquisition of Shares of Sirona Biochem Corp.
Jul 5, 2013 12:25:55 (ET)
VANCOUVER, BRITISH COLUMBIA, Jul 05, 2013 (Marketwired via COMTEX) -- Pathfinder Asset Management Limited ("Pathfinder") wishes to clarify and confirm its previously announced press release of June 28, 2013, whereby Pathfinder announced the acquisition of certain securities of Sirona Biochem Corp. ("Sirona").
On on March 6, 2013, Pathfinder acquired control or direction over a total of 6,000,000 units of Sirona Biochem Corp. by way of a private placement for aggregate consideration of $600,000 or $0.10 per unit (the "Acquisition"). Each unit consisted of one common share in the capital of Sirona ("Common Share") and one common share purchase warrant in the capital of Sirona ("Warrant"). Each Warrant entitles the holder to purchase one additional Common Share at a price of $0.15 per Common Share for a period of two years from the closing date of the private placement. The securities are subject to a four-month and one-day hold period.
As a result of the Acquisition, Pathfinder currently exercises control or direction over approximately 6.13% of the current total number of issued and outstanding Common Shares. In the event that all such Warrants are exercised, Pathfinder would exercise control or direction over a total of 12,000,000 Common Shares representing 11.56% of the current issued and outstanding Common Shares (assuming that Sirona issues no other securities).
The Acquisition was made by Pathfinder for investment purposes on behalf of a discretionary client account managed by Pathfinder for Douglas B. Johnson, a director, senior officer and significant shareholder of Pathfinder. Although Pathfinder has control or direction over these securities, the securities are beneficially owned by Mr. Johnson. The June 28, 2013 news release inadvertently indicated that Mr. Johnson had also acquired an additional 6,000,000 units of Sirona (i.e., in addition to those acquired by Pathfinder as part of the Acquisition).
Pathfinder may, in the future, acquire additional securities of Sirona for investment purposes on its own behalf or on behalf of client accounts over which it has discretionary trading authority.
Contacts:
Ken Bancroft
c/o Suite 1320, 885 West Georgia Street
Vancouver, British Columbia
V6C 3E8
604.682.7312
SOURCE: Pathfinder Asset Management Limited
Sirona Biochem Announces LOI for Collaboration with Biogalenys
Jul 2, 2013 14:21:17 (ET)
VANCOUVER, BRITISH COLUMBIA, Jul 02, 2013 (Marketwired via COMTEX) -- Sirona Biochem Corp. (otcqx:SRBCF)(frankfurt:ZSB) is pleased to announce the signing of a Letter of Intent (LOI) for a collaboration with Biogalenys. The goal of the collaboration is to study Sirona Biochem's patented glycoprotein (cell preservation) technology and to develop preclinical data supporting multiple targeted applications.
Using its proprietary chemistry technique, Sirona Biochem has developed and patented a cell preservation technology that (early tests have shown) protects human fibroblast cells from damage in stressed environments. Potential applications of this technology include, but are not limited to: anti-aging cream, sunscreen / UV protection, wound care, reduced scarring, frostbite protection, stem cell preservation, beta islet cell preservation, platelet and red blood cell preservation, and increased preservation times for tissue explants and organ transplantation.
The proposed 3 year collaboration will focus on first studying the application of Sirona Biochem's cell preservation technology for use as a cosmetic anti-aging active ingredient and as a preservative adjuvant for tissue explants.
"We are excited to be creating a second project partnership with Biogalenys," said Neil Belenkie, CEO of Sirona Biochem. "We look forward to continuing the success that our companies achieved on our skin lightening project; applying our shared expertise in the study and development of our new cell preservation technology".
"We are extremely happy to continue our collaboration with Sirona Biochem and to work in partnership on their scientific innovations in the future, which will allow the simultaneous development of our two companies on an international level," said Pascal Svinareff, CEO of Biogalenys.
About Biogalenys
Biogalenys is a French laboratory (CRO) specialized in studies of transmembrane passage across several models of epithelia. Biogalenys provides, tests according to GLP or not, for active ingredients and chemical compounds and biological assays to serve the pharmaceutical and cosmetic industries. The laboratory designs the studies, conduct assays, completes data interpretation and classifies the absorption potential of drug and compounds, using different models for in-vitro, in-vivo and ex-vivo assays. Biogalenys is involved in several projects (approved by Cosmetic Valley) in research in cosmetic using efficient test with culture cells models.
For more information please visit: http://www.biogalenys.com
About Sirona Biochem
Sirona Biochem is a biotechnology company that specializes in fluorinating carbohydrate compounds, patenting the resulting new chemical entities, and licensing each compound for additional study and commercialization. Sirona Biochem's pipeline for development includes diabetes therapeutics, skin depigmenting and anti-aging agents for cosmetic and pharmaceutical use, biological ingredients and cancer vaccine antigens. The company utilizes a proprietary chemistry technique to improve pharmaceutical properties of carbohydrate-based molecules. Sirona Biochem is the parent company of French-based biotechnology company, TFChem. For more information visit: www.sironabiochem.com .
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
Contacts:
Sirona Biochem Corp.
Christopher Hopton
Chief Financial Officer
604.282.6064
chopton@sironabiochem.com
SOURCE: Sirona Biochem Corp.
mailto:chopton@sironabiochem.com
Sirona Biochem Announces LOI for Collaboration with VitamFero
Jun 25, 2013 14:45:43 (ET)
VANCOUVER, BRITISH COLUMBIA, Jun 25, 2013 (Marketwired via COMTEX) -- Sirona Biochem Corp. (otcqx:SRBCF)(frankfurt:ZSB) is pleased to announce the signing of a Letter of Intent (LOI) to create an extended collaboration with VitamFero. The goal of the collaboration is to apply Sirona Biochem's patented glycoprotein technology to the preservation of live attenuated animal vaccines.
"We are proud to be developing a partnership where our two unique technologies will be combined with the intent of advancing the science, economics and preservation capabilities of animal vaccines," said Neil Belenkie, CEO of Sirona Biochem.
"VitamFero is pleased to strengthen its partnership with Sirona Biochem. We are confident that strong synergies are to emerge from the extended collaboration that is going to be initiated," said Pascal Breton, CEO of VitamFero.
VitamFero develops live and attenuated animal vaccines against various infectious diseases, especially against Apicomplexa parasites. VitamFero intends to develop an effective protocol that, beyond their highly proven efficacy, extends the practicability of handling the anti-parasite vaccines. Further to the MTA signed in March 2013, VitamFero will evaluate Sirona Biochem's synthetic preservation technology to optimize its biopharmaceutical formulation and storage of its vaccine.
Using its proprietary chemistry technology, Sirona Biochem is developing biological preservation compounds to extend the life of stem cells, blood platelets, islets cells, tissues, organs and other biologics. By preserving these biologics, storage and transport times can be extended, such as in organ transplantation, thereby reducing or eliminating unnecessary disposal of valuable biological assets.
About VitamFero
VitamFero is a privately owned biotech company whose mission, founded on an innovative and patented technology (i.e. Toxo KO and Neo KO), is to create, develop, register and market novel anti-infectious vaccines, first against Apicomplexa parasites such as Toxoplasma gondii (toxoplasmosis agent), Neospora caninum (neosporosis agent) and Cryptosporidium parvum (cryptosporidiosis agent). With headquarters in Evry - Genopole(R) (France) and laboratories in Tours (France), VitamFero is involved primarily in veterinary healthcare. For more information, visit: www.vitamfero.com .
About Sirona Biochem
Sirona Biochem is a biotechnology company developing diabetes therapeutics, skin depigmenting and anti-aging agents for cosmetic and pharmaceutical use, biological ingredients and cancer vaccine antigens. The company utilizes a proprietary chemistry technique to improve pharmaceutical properties of carbohydrate-based molecules. Sirona Biochem is the parent company of French-based biotechnology company TFChem. For more information visit: www.sironabiochem.com .
Sirona Biochem Corp also announces it has granted additional incentive stock options under its Stock Option Plan to directors and consultants exercisable for up to 700,000 shares of the Company. The options are exercisable on or before June 25, 2018 at an exercise price of $0.15 per share.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward- looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
Contacts:
Sirona Biochem Corp.
Christopher Hopton
Chief Financial Officer
604.282.6064
chopton@sironabiochem.com
www.sironabiochem.com
SOURCE: Sirona Biochem Corp.
mailto:chopton@sironabiochem.com
http://www.sironabiochem.com
Sirona Biochem Announces LOI for Collaboration with Cincinnati Children's Hospital Medical Center
May 29, 2013 18:59:53 (ET)
VANCOUVER, BRITISH COLUMBIA, May 29, 2013 (Marketwired via COMTEX) -- Sirona Biochem Corp. (otcqx:SRBCF)(frankfurt:ZSB) is pleased to announce the signing of a Letter of Intent (LOI) to create a collaboration with Cincinnati Children's Hospital Medical Center. The goal of the collaboration is to create a novel skin care technology by combining Sirona Biochem's patented cell preservation glycoprotemim with Cincinnati Children's patented synthetic vernix technology.
"Cincinnati Children's Hospital Medical Center is a world leader in discovery of innovative therapeutic treatments and technology," said Neil Belenkie, CEO of Sirona Biochem. "We are proud to be developing a partnership where our two unique technologies will be combined with the intent of creating industry-leading skin therapies with potential for multiple applications."
"We are excited to collaborate with Sirona Biochem and their team of experts to explore the potential of combining our two technologies," said Niki Robinson, PhD, assistant vice president of Cincinnati Children's Center for Technology Commercialization. "This is an important step in ensuring our technology enters the market and is ultimately positioned to improve patient outcomes."
About Cincinnati Children's Hospital Medical Center
Cincinnati Children's Hospital Medical Center ranks third in the nation among all Honor Roll hospitals in U.S. News and World Report's 2012 Best Children's Hospitals ranking. It is ranked #1 for neonatology and in the top 10 for all pediatric specialties. Cincinnati Children's is one of the top two recipients of pediatric research grants from the National Institutes of Health, and a research and teaching affiliate of the University of Cincinnati College of Medicine. The medical center is internationally recognized for improving child health and transforming delivery of care through fully integrated, globally recognized research, education and innovation. Additional information can be found at www.cincinnatichildrens.org .
About Sirona Biochem Corp.
Sirona Biochem is a biotechnology company developing diabetes therapeutics, skin depigmenting and anti-aging agents for cosmetic and pharmaceutical use, biological ingredients and cancer vaccine antigens. The company utilizes a proprietary chemistry technique to improve pharmaceutical properties of carbohydrate-based molecules. Sirona Biochem is the parent company of French-based biotechnology company, TFChem. For more information visit: www.sironabiochem.com .
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contacts:
Sirona Biochem Corp.
Christopher Hopton
Chief Financial Officer
604.282.6064
chopton@sironabiochem.com
www.sironabiochem.com
SOURCE: Sirona Biochem Corp.
mailto:chopton@sironabiochem.com
http://www.sironabiochem.com
Sirona Biochem Provides Webcast Link for Marcum MicroCap Presentation
May 29, 2013 16:32:58 (ET)
VANCOUVER, BRITISH COLUMBIA, May 29, 2013 (Marketwired via COMTEX) -- Sirona Biochem Corp. (otcqx:SRBCF)(frankfurt:ZSB) today announced the link for the live webcast at the 2nd Annual Marcum MicroCap Conference.
The presentation will take place May 30 at 10:30 AM EDT.
Sirona Biochem's Chief Executive Officer, Neil Belenkie will present. A live webcast is available at the following link: http://www.wsw.com/webcast/marcum/sbm.v .
About the Marcum MicroCap Conference
The Marcum MicroCap Conference is dedicated to introducing investors to the very best, undiscovered companies under $500 million in market capitalization. The Conference is expected to draw more than 1,000 attendees including senior personnel from almost 100 presenting public companies. This invitation-only event attracts institutional investors including top fund managers and qualified high net worth investors, who focus on small cap equities.
About Sirona Biochem Corp.
Sirona Biochem is a biotechnology company developing diabetes therapeutics, skin depigmenting and anti-aging agents for cosmetic use, biological ingredients and cancer vaccine antigens. The company utilizes a proprietary chemistry technique to improve pharmaceutical properties of carbohydrate-based molecules. Sirona Biochem is the parent company of French-based biotechnology company, TFChem. For more information visit www.sironabiochem.com .
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contacts:
Sirona Biochem Corp.
Christopher Hopton
CFO
604.282.6064
chopton@sironabiochem.com
www.sironabiochem.com
SOURCE: Sirona Biochem Corp.
mailto:chopton@sironabiochem.com
http://www.sironabiochem.com
Sure was! I believe the company finally has their act together. Looking for some really nice things to happen in the next few months, with the potential to be a game changer for many investors.
Followers
|
8
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1324
|
Created
|
01/16/11
|
Type
|
Free
|
Moderators |
Welcome to the new SIROMA BIO-CHEM stock board.
OVERVIEW
Launched in 2009, Sirona Biochem is developing programs in three major streams:
*Therapeutics - Diabetes and Cancer
*Cosmeceuticals - Anti-aging Depigmenting Agents (skin lighteners)
*Biological Ingredients - Inducers and Adjuvants for biological developments
Our expertise lies within our proprietary chemistry technology. We have developed a chemistry technique to improve the pharmaceutical qualities of carbohydrate-based molecules.
Carbohydrates, or sugar molecules, perform numerous roles in living organisms and are essential to life. Their importance to life makes them valuable for the development of therapeutics and cosmeceuticals.
While carbohydrate-based molecules have broad application potential, they are challenging to develop. Due to the complexity of carbohydrates, these molecules can easily break down and become toxic when exposed.
Sirona Biochem has developed a fluorination technique to maintain the integrity of carbohydrate-based molecules even after exposure to enzymes known to typically negatively affect them. This proprietary technique has allowed Sirona Biochem to explore the immense opportunities carbohydrate-based molecules can offer.
Sirona Biochem’s development focus is centred around three high-valued programs, selected based on our research expertise in the area, market potential, development timelines and high return on investment.
Carbohydrate-based molecules have several applications such as:
We believe this chemistry method can be applied to drugs in development to improve their properties, discontinued drugs that may have been shelved for stability reasons, or for the development of new products for cosmetics and biological manufacturing. Using our proprietary chemistry process, we feel we can maximize the commercial value of carbohydrate-based molecules.
Sirona Biochem specializes in the development of carbohydrate-based molecules. While carbohydrate-based molecules offer immense commercial potential, we are focused on advancing three programs – therapeutics, cosmetic agents and biological ingredients. Our two most advanced programs include a diabetes treatment candidate and a cosmetic skin lightening agent.
Our sodium glucose co-transporter (SGLT) inhibitor for diabetes, achieved positive preclinical results. In a head-to-head preclinical study, Sirona Biochem’s SGLT inhibitor performed better than Johnson and Johnson’s canagliflozin (Invokana™), which was given FDA market approval in the U.S. (March 2013) and is being considered for market approval in Europe. We have begun partnering discussions to review options for the outlicensing of our SGLT inhibitor. A pharmaceutical partner would handle the downstream clinical and commercial needs of our program.
Recognized for the scientific innovation at our laboratory in France, the French government awarded our team an innovation grant worth CDN$1.9 Million to develop our cosmetic skin lightener program to a commercial ready stage. Several efficacy and stability studies have been completed with results showing superiority over popular commercial products. Further toxicity studies are underway.
Sirona Biochem’s proprietary chemistry technology has relevance in many therapeutic, cosmetic and biological areas where the potential for development is high. In addition to the diabetes, skin lightener,anti-aging and biological ingredients programs, the company is exploring development of the following:
Cancer Vaccine Antigen
Our scientists have formulated a Tn antigen that could be valuable as a key component for the development of a cancer vaccine.
In healthy individuals, certain antigens are suppressed by the body’s immune system. In patients with cancer, research has shown that a higher presence of Tn antigens on the cell surface are linked to higher malignancy and growth. These antigens promote cancer cell adhesion and thus are linked to cancer metastases, allowing cancer to spread from one organ to another. By producing a synthetic version of the Tn antigen it can be used in a vaccine that can potentially trigger the immune system to recognize it as a foreign substance. Previous attempts by scientists to develop a vaccine with the Tn antigen have been unsuccessful due to the chemistry challenges in stabilizing the molecule.
Pipeline
Therapeutics
Sirona Biochem's technology platform of enhancing carbohydrate-based molecules has potential for the development of several blockbuster therapeutics for the treatment of diabetes, obesity, cancer, cardiovascular disease, pain and inflammation. Currently, our therapeutic focus is on the development of a Sodium Glucose Transporter (SGLT) inhibitor for Type 2 diabetes and a cancer vaccine antigen.
Sirona Biochem is developing SGLT inhibitors for Type 2 diabetes and obesity. SGLT inhibitors are a new class of drugs for diabetes and obesity. They work differently from traditional Type 2 diabetes therapeutics which increase insulin production in the pancreas and affect metabolism. In the kidneys, SGLT inhibitors reduce the reabsorption of glucose into the bloodstream by eliminating excess glucose into the urine.
The kidneys filter approximately 180 gm of glucose per day from the blood which is then mostly reabsorbed back into the blood by SGLT transporters. SGLT inhibitors reduce the glucose reabsorption process, such that excess glucose is excreted in the urine, rather than reabsorbed into the bloodstream. That is to say, they can help regulate glycemia. This is a new promising potential treatment for Type 2 diabetes and obesity.
Sirona Biochem's goal is to develop a best-in-class SGLT inhibitor for Type 2 diabetes. By applying our proprietary chemistry technique, we believe we can produce a drug candidate with optimal pharmaceutical characteristics including, but not limited to, enhanced stability, bioavailability, selectivity and/or efficacy.
There are no SGLT inhibitors available on the market. The most advanced SGLT inhibitor, dapagliflozin, developed by Bristol Myers Squibb and AstraZeneca, is being reviewed for market approval by the Food & Drug Administration with a decision expected in the first quarter of 2012. In a comparative preclinical study, Sirona Biochem's SGLT inhibitor drug candidate appeared to outperform dapagliflozin. Sirona Biochem aims to develop an improved product.
Preclinical animal tests of Sirona Biochem's SGLT inhibitor for Type 2 diabetes are well underway with the positive results posted in the first quarter of 2011. Additional preclinical studies to test the safety and toxicology of this SGLT inhibitor are currently being conducted. Sirona Biochem plans to independently complete preclinical studies to prepare its SGLT inhibitor for human clinical trials. A pharmaceutical partner will be sought for clinical and commercial development of our program.
According to the World Health Organization, more than 220 million people worldwide suffer from diabetes. Approximately 90% of diabetes patients suffer from Type 2 diabetes. The WHO estimates that diabetes-related deaths will double from 2005 to 2030. In 2009, an estimated $25 billion was spent globally on diabetes treatment. Diabetes is the fourth largest pharmaceutical market.
In Canada, diabetes is the 6th leading cause of death. The Canadian Diabetes Association estimates that by 2020, one in ten Canadian will have diabetes. It's estimated that diabetes costs the Canadian healthcare system more than $12 billion a year.
With sedentary lifestyles becoming so common, the prevalence of diabetes is increasing rapidly. While there are several medications on the market, there remains a major unmet medical need for new improved diabetes medications. Sales of Januvia, a diabetes medication launched in 2006, reached US$1.6 billion in annual sales by 2009. By 2013, it's estimated sales of Januvia will reach US$4.5 billion.
Cancer Antigen
Our scientists have formulated a Tn antigen that could be valuable as a key component for the development of a cancer vaccine.
In healthy individuals, certain antigens are suppressed by the body's immune system. In patients with cancer, research has shown that a higher presence of Tn antigens on the cell surface are linked to higher malignancy and growth. These antigens promote cancer cell adhesion and thus are linked to cancer metastases, allowing cancer to spread from one organ to another. By producing a synthetic version of the Tn antigen it can be used in a vaccine that can potentially trigger the immune system to recognize it as a foreign substance. Previous attempts by scientists to develop a vaccine with the Tn antigen have been unsuccessful due to the chemistry challenges in stabilizing the molecule.
Management
Howard J. Verrico, MD
Ceo and Chairman of the Board
V-card
Dr. Verrico obtained his medical degree from the University of Toronto in 1985 and has been a member of the College of Physicians and Surgeons of British Columbia since July 1986. Dr Verrico is currently a practicing emergency room physician. In addition, Dr. Verrico has extensive experience as a venture capitalist in the junior capital markets.
Chief Scientific Officer
Dr. Géraldine Deliencourt-Godefroy is an award-winning synthetic chemist and the founder of French-based biotechnology company TFChem. Since the acquisition of TFChem by Sirona Biochem in March 2011, Dr. Deliencourt-Godefroy has assumed the role of Chief Scientific Officer. Her scientific research in carbohydrate chemistry has led to the discovery of new drug families and the development of drug candidates for diabetes and obesity, cosmetic ingredients and biological adjuvants. Previous to founding TFChem, Dr. Deliencourt-Godefroy was a scientific leader at INSA (National Institute of Applied Sciences) in Rouen, France, where she developed a new technology on stabilized carbohydrates. Previous roles also include a post-doctoral position at the University College London and doctoral research at the Research Institute of Fine Organic Chemistry in Rouen, France. Dr. Deliencourt-Godefroy received a PhD and Masters in Organic Chemistry as well as her business degree from the University of France. She is the author of several publications and patents and is also the recipient of the acclaimed Francinov Research and Innovation Medal, French Ministry of Research Award and the French Senate Award.
Christopher Hopton, CGA
Chief Financial Officer
V-card
Mr. Christopher Hopton is Sirona Biochem’s Chief Financial Officer. He brings 15 years of expertise in financial management and operations. His extensive experience covers areas of financial planning, accounting policy and business process improvement. As a business investment and finance consultant, Mr. Hopton has worked with several public and privately-held companies. Most recently, Mr. Hopton was the Chief Financial Officer of Central Resources Corp., a junior mineral exploration company. Formerly, he held the position of Division Controller at Canadian Airlines where he was responsible for an annual operating budget of $200M. Mr. Hopton was also involved in the restructuring of 360 Networks, a network communications company, which led to a buyout by Bell Canada. Mr. Hopton earned his Bachelor of Business Administration from Simon Fraser University in British Columbia, Canada and received his professional designation as a Certified General Accountant.
Jason Tian , Director
Jason Tian has been providing legal services to international clients since 2007 and has worked in top firms in China such as Beijing
Zhonglun, Beijing Zhongyin, Beijing Dacheng and is now a Senior Partner of Shanghai Landing Law Offices. He also worked as senior legal translator in UK-based firm, Clifford
Chance LLP, before starting his legal career.
Shanghai Landing Law Offices is a full-service law firm with headquarters in Shanghai, China. Lawyers at Landing provide full-service to clients in industries such as healthcare and
pharmaceuticals as well as consumer retail in China. Landing has several domestic branches and overseas branches in the United States, India, Singapore, Indonesia,
Bangladesh, Philippines and Cambodia.
Dr. Denis Richard earned his Ph.D. in Physiology at Laval University and received further postdoctoral training in nutrition and physiology at the Dunn Nutrition Unit at the University of Cambridge, Cambridge, England.
Dr. Richard is a full professor at the Department of Medicine at Université Laval. Together with serving as director of the Research Centre of the Institut de Cardiologie et de Pneumologie de Québec, and director of the Groupe Interdisciplinaire de Recherche sur l’Obésité de l’Université Laval, he is the recipient of the Merck Frosst / CIHR Research Chair in Obesity, the first Chair devoted to obesity research in Canada. He is active with several societies and associations and is a member of: The Canadian Obesity Network, The American Physiological Society, The Society for Neuroscience, The Endocrine Society, and The Society for the Study of Ingestive Behavior.
Dr. Richard is a well-established scientist with regard to the study of (i) neurosystems involved in the control and regulation of food intake, thermogenesis, and energy balance, (ii) the mechanisms whereby the gastrointestinal hormones influence energy balance regulation, (iii) the relationship between stress and obesity, (iv) the role of the sympathetic nervous system in controlling uncoupling protein 1 in brown adipose tissue, and (v) the role of uncoupling protein 2 in energy metabolism, oxidative stress and neuroprotection. He lists over 200 publications in his career.
Dr. Bruce Verchere is a Professor in the Departments of Surgery and Pathology & Laboratory Medicine at the University of British Columbia (UBC). He is also head of the Diabetes Research Program at the Child & Family Research Institute, and holds the Irving K Barber Chair in Diabetes Research. Dr. Verchere’s research aims to understand the function of pancreatic islet beta cells and their relevance in both type 1 and type 2 diabetes, with a goal of developing therapeutic approaches for enhancing beta cell survival and function. He has published more than 90 manuscripts in the field of islet biology and diabetes and has been invited to present his research worldwide. Dr. Verchere was a Senior Scholar of the Michael Smith Foundation for Health Research (MSFHR) and was awarded the UBC Outstanding Young Alumnus award in 2000 and the Canadian Diabetes Association Young Scientist award in 2006. He is currently chair of the CIHR Diabetes Obesity Lipid and Lipoprotein Disorders panel, Chair of the National Research Council of the Canadian Diabetes Association, and Chair of the MSFHR Research Advisory Council. He currently sits on the editorial board of the publications Diabetes and Canadian Journal of Diabetes.
Dr. Michael Walker has been a director and CEO of Verona Pharma since September 2006. He is an Emeritus Professor at the Department of Anesthesiology, Pharmacology & Therapeutics, University of British Columbia, Canada and has founded and managed various biotech companies in Canada and the UK. His research interests are wide including many aspects of general pharmacology (from basic to clinical studies), marine toxins and respiratory and cardiac pharmacology.
Dr. Walker was the founder of Rhythm Search Developments (RSD) Ltd., which company evolved into Nortran Pharmaceuticals Inc. and subsequently Cardiome Pharma Corp. (TSX:COM, NASDAQ: CRME) whose drug, RSD1235, for the acute termination of atrial fibrillation (a disorder of heart beating), is currently the subject of a New Drug Application filed with the US Food and Drug Administration.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |